Variant Pharmaceuticals Completes Pre-IND Meeting with FDA on VAR 200 for Focal Segmental Glomerulosclerosis (FSGS), a Rare Kidney Disease

Variant Pharmaceuticals Logo (PRNewsFoto/Variant Pharmaceuticals)WESTON, Fla., April 16, 2018 /PRNewswire/ — Variant Pharmaceuticals, Inc. (Variant), a clinical stage orphan drug company developing first-in-class drugs for patients with rare diseases, announced today receipt of FDA minutes from the March 12, 2018 Pre-IND meeting regarding development…